Archive · 21 Jul 2026
Menarini and Pharmacosmos Partner for Cosela® in Asia-Pacific
Menarini Asia-Pacific and Pharmacosmos A/S have teamed up to bring a new medicine called Cosela® to patients in the Asia-Pacific region.
Cosela® helps protect the bone marrow of patients with a type of lung cancer who are undergoing chemotherapy.
This partnership aims to make the medicine available in countries like Australia, Hong Kong, Indonesia, Malaysia, and others.
The first launch is expected in Hong Kong in 2028, subject to regulatory approvals.
This collaboration is part of Menarini's mission to provide innovative therapies to improve patient lives.
Cosela® is already available in the United States and China and is under registration in Europe.
The partnership builds on a previous agreement between the two companies to commercialize another medicine, Monofer®, in the region.
Menarini Asia-Pacific partners with Pharmacosmos A/S to bring Cosela® to Asia-Pacific markets.
Cosela® is a first-in-class therapy approved by the FDA to protect bone marrow from chemotherapy-induced myelosuppression.
The partnership covers registration, commercialization, and distribution in 11 Asia-Pacific countries.
First launch expected in Hong Kong in 2028, subject to regulatory approvals.
The partnership builds on a previous agreement to commercialize Monofer® in the region.
- Who
- Menarini Asia-Pacific and Pharmacosmos A/S
- What
- Partnership to bring Cosela® to Asia-Pacific markets
- When
- Announced on July 21, with expected launch in 2028
- Where
- Asia-Pacific region, starting with Hong Kong
- Why
- To expand access to Cosela®, a first-in-class therapy for chemotherapy-induced myelosuppression, addressing a significant unmet need in oncology supportive care.
Pharmaceutical Partnership Benefits
Regulatory and Market Challenges
Market Expansion
Pharmaceutical Partnership Benefits
The partnership aims to expand access to Cosela® across Asia-Pacific, benefiting patients with extensive-stage small cell lung cancer (ES-SCLC).
Regulatory and Market Challenges
Regulatory approvals and market-specific challenges may delay the launch and commercialization of Cosela® in the region.
Innovation and Patient Care
Pharmaceutical Partnership Benefits
Cosela® represents a significant advancement in oncology supportive care, addressing a critical unmet need for patients undergoing chemotherapy.
Regulatory and Market Challenges
The effectiveness and adoption of Cosela® will depend on local healthcare systems' ability to integrate and reimburse the therapy.
- Company
- Menarini Asia-Pacific
- Partner
- Pharmacosmos A/S
- Product
- Cosela® (trilaciclib)
- Condition Treated
- Chemotherapy-induced myelosuppression (CIM)
- Target Patients
- Patients with extensive-stage small cell lung cancer (ES-SCLC)
- Markets
- Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
- Expected Launch
- 2028 (subject to regulatory approvals)